Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301431 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,050
- Enrollment target
NCT00301431 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 1,050 participants.
The verdict
NCT00301431, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,050 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
Interventions
- DRUG DVS-233
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,050 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00301431
The ClinicalTrials.gov registry entry for NCT00301431 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DVS-233 is the first listed.
NCT00301431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00301431 about?
NCT00301431 is a clinical study titled "Study Evaluating the Efficacy of DVS-233 in Fibromyalgia". The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
What is the current status of trial NCT00301431?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,050 participants. The study started on 2006-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00301431?
The interventions under investigation include: DVS-233 (DRUG).
Who is sponsoring clinical trial NCT00301431?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.